Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GW PHARMACEUTICALS PLC (GWPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/03/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress",
"GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity"
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress"
02/25/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019"
05/06/2019 8-K Quarterly results
Docs: "GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019",
"GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex - Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 -"
02/26/2019 8-K Quarterly results
11/27/2018 8-K Quarterly results
Docs: "GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress - Epidiolex oral solution , first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - London, UK, Carlsbad, CA, 27 November 2018: GW Pharmaceuticals plc , the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the fourth quarter and year ended 30 September 2018. “We are proud to have recently launched Epidiolex, the first and only FDA-approved plant-derived cannabinoid medicine and a much needed new treatment option for patients with LGS and Dravet syndrome, two of the most difficult-to-treat forms of childhood-onset epilepsy. We are pleased wi..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy